Biological
Pneumococcal 20-Valent Conjugate Vaccine clinical trials
Also written PCV20.
- studies test it
- 25
- open now
- 6
- in phase 3
- 16
- first study started
- 2018
Keep track of what changes. Save the Pneumococcal 20-Valent Conjugate Vaccine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
25 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 2
- Phase 3
- 16
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 5
Pfizer (17) · GlaxoSmithKline (2) · M.D. Anderson Cancer Center (1) · Merck Sharp & Dohme LLC (1) · University of Utah (1) · University of Alabama at Birmingham (1) · Hennepin Healthcare Research Institute (1) · Medical University of Vienna (1)
Often tested with
Tested in the same studies.
13-valent pneumococcal vaccine (2) · AFX3772 (1) · Arexvy (1) · BNT162 Vaccine (1) · V118C (1) · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (1) · Pediarix (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1)
Studies
Open first, then newest update. How each study uses Pneumococcal 20-Valent Conjugate Vaccine is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)RecruitingPhase 1Merck Sharp & Dohme LLCNCT07300267Written as PCV20 (Stage 1)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their BabiesRecruitingPhase 3PfizerNCT07160244Written as Prevnar 20
- A Study to Evaluate 20vPnC in Healthy Chinese InfantsRecruitingPhase 3PfizerNCT07754539Written as 20vPnC
- Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL TrialRecruitingPhase 2University of UtahNCT05183854Written as Pneumococcal 20-valent Conjugate Vaccine
- Genetic Variation in IgG in Alpha 1 Antitrypsin DeficiencyRecruitingPhase 4University of Alabama at BirminghamNCT07135427Written as 20-valent pneumococcal conjugate vaccine
- Vaccine Immunity and Inflammation in the Aging Person Living With HIVRecruitingPhase 4Hennepin Healthcare Research InstituteNCT06514547Written as Conjugate Pneumococcal Vaccine 20 (PCV20)
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and InfantActive, not recruitingPhase 1PfizerNCT07023081Written as 20vPnC
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy InfantsCompletedPhase 2GlaxoSmithKlineNCT05412030Written as Prevnar 20
- Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 TherapyActive, not recruitingPhase 4M.D. Anderson Cancer CenterNCT06049134Written as PCV20
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese AdultsCompletedPhase 1PfizerNCT07019909Written as 20vPnC
- A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and TaiwanCompletedPhase 3PfizerNCT05512819Written as 20-valent pneumococcal conjugate vaccine
- Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older AdultsCompletedPhase 3GlaxoSmithKlineNCT05879107Written as PCV20
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and TaiwanCompletedPhase 3PfizerNCT04875533Written as 20vPnC
- A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.CompletedPhase 3PfizerNCT05875727Written as 20-valent pneumococcal conjugate vaccine
- Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13CompletedPhase 3PfizerNCT05408429Written as 20-valent pneumococcal conjugate vaccine
- Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of AgeCompletedPhase 3PfizerNCT04642079Written as 20vPnC
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy InfantsCompletedPhase 3PfizerNCT04546425Written as 20-valent pneumococcal conjugate vaccine
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy InfantsCompletedPhase 3PfizerNCT04382326Written as 20-valent pneumococcal conjugate vaccine
- 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy InfantsCompletedPhase 3PfizerNCT04379713Written as 20-valent pneumococcal conjugate vaccine
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese InfantsCompletedPhase 3PfizerNCT04530838Written as 20-valent pneumococcal conjugate vaccine
See all 25 studies that test Pneumococcal 20-Valent Conjugate Vaccine →
Given in every arm · 9 — Pneumococcal 20-Valent Conjugate Vaccine is usual care beside what is tested
- A Study of V132 in Healthy Older Participants (V132-001)RecruitingPhase 1Merck Sharp & Dohme LLCNCT07712575Written as PREVNAR 20™
- Vaccine Responses in Patients With B Cell MalignanciesRecruitingPhase 4National Heart, Lung, and Blood Institute (NHLBI)NCT05170399Written as PREVNAR 20
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06740630Written as PCV 20
- A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06693895Written as PCV 20
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06806137Written as PCV 20
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06855160Written as PCV 20
- Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic LeukemiaRecruitingPhase 2Seema BhatNCT05417165Written as Pneumococcal 20-valent Conjugate Vaccine
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT03621670Written as Prevnar 20
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824181Written as Prevnar 20 vaccine
As the comparator · 27 — what is tested is compared with Pneumococcal 20-Valent Conjugate Vaccine
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.RecruitingPhase 3PfizerNCT07629440Written as 20-valent pneumococcal conjugate vaccine (20vPnC)
- A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to AdultsRecruitingPhase 3PfizerNCT07794748Written as 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgeRecruitingPhase 3SanofiNCT07348692Written as 20vPCV licensed vaccine
- A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy InfantsRecruitingPhase 3PfizerNCT07573462Written as 20-valent pneumococcal conjugate vaccine (20vPnC)
- Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and AdolescentsRecruitingPhase 3PfizerNCT07660198Written as 20-valent pneumococcal conjugate vaccine (20vPnC)
- A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of AgeNot yet recruitingPhase 1GlaxoSmithKlineNCT07406347Written as PCV20
- Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseRecruitingPhase 3SanofiNCT07247188Written as 20vPCV
- Safety and Immunogenicity of PCV-LITE, a Low-dose of Pneumococcal Conjugate Vaccine With LiteVax AdjuvantNot yet recruitingPhase 1LiteVax BVNCT06986239Written as PCV20
- A Study of V118E in Healthy Participants (V118E-003)Active, not recruitingPhase 1Merck Sharp & Dohme LLCNCT07168915Written as PREVNAR 20™
- A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsActive, not recruitingPhase 2PfizerNCT06524414Written as 20-valent pneumococcal conjugate vaccine (20vPnC)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49CompletedPhase 3Vaxcyte, Inc.NCT07284654Written as PCV20
- A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster DoseActive, not recruitingPhase 1GlaxoSmithKlineNCT07406334Written as PCV20
- A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in AdultsCompletedPhase 1/2PfizerNCT06182124Written as 20-valent pneumococcal conjugate vaccine (20vPnC)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationActive, not recruitingPhase 3Vaxcyte, Inc.NCT07425392Written as PCV20
- A Study to Learn About How a New Pneumococcal Vaccine Works in AdultsActive, not recruitingPhase 1PfizerNCT07086677Written as 20-valent pneumococcal conjugate vaccine
- A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of AgeCompletedPhase 1GlaxoSmithKlineNCT07105722Written as PCV20
- Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 YearsActive, not recruitingPhase 1GlaxoSmithKlineNCT07428759Written as PCV20
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3Sanofi Pasteur, a Sanofi CompanyNCT06736041Written as Prevnar 20 vaccine
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824194Written as Prevnar 20 vaccine
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate VaccineCompletedPhase 2Inventprise Inc.NCT06077656Written as PCV 20
Showing 20 of 27.